Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

High tumor mutation burden in a patient with metastatic gastric cancer sensitive to trastuzumab: a case report.

Annals of palliative medicine - 1 May 2021

Hu Chun-Ting, Zhou Yi-Chen, Zu Li-Dong, Fu Guo-Hui, Li Qi

Abstract excerpt

Patients with HER2-positive gastric cancer (GC) can benefit from the addition of trastuzumab. However, not all patients with HER2-positive GC respond to trastuzumab. Biomarkers affecting its efficacy in patients with advanced gastric cancer (AGC) are largely unknown. Therefore, classifying GC into molecularly distinct subtypes to accurately distinguish between GC patients who would and would not benefit from...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to Mutation
Share to Receptor, ErbB-2

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Stomach Neoplasms

Share to Trastuzumab

Source

Identifiers

PMID: 32921108
DOI: 10.21037/apm-20-132

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

High tumor mutation burden in a patient with metastatic gastric cancer sensitive to trastuzumab: a case report.PMID 32921108Read ↗

Prospective comprehensive genomic profiling of advanced gastric carcinoma cases reveals frequent clinically relevant genomic alterations and new routes for targeted therapies.Semantic proximity Read ↗

Mutational landscape of gastric cancer and clinical application of genomic profiling based on target next-generation sequencingSemantic proximity Read ↗

Translating gastric cancer genomics into targeted therapiesSemantic proximity Read ↗

Personalized medicine in gastric cancer: Where are we and where are we going?Semantic proximity Read ↗

Exploring potential molecular resistance and clonal evolution in advanced HER2-positive gastric cancer under trastuzumab therapySemantic proximity Read ↗

Landscape of somatic mutations in gastric cancer assessed using next‑generation sequencing analysisSemantic proximity Read ↗

The genomics and therapeutics of HER2-positive gastric cancer—from trastuzumab and beyondSemantic proximity Read ↗

Potential Resistance to Oxaliplatin-Based Regimens in Gastric Cancer Patients with ERBB2 R678Q Mutation: Evidence from a National Genomic DatabaseSemantic proximity Read ↗

Biomarkers of Primary Resistance to Trastuzumab in HER2-Positive Metastatic Gastric Cancer Patients: the AMNESIA Case-Control Study.Semantic proximity Read ↗

KMT2D promotes proliferation of gastric cancer cells: evidence from ctDNA sequencingSemantic proximity Read ↗

Clinical implications of plasma ctDNA features and dynamics in gastric cancer treated with HER2‐targeted therapiesSemantic proximity Read ↗

Real-World Genomic Landscape of Korean Gastric Cancer: Integrating Biomarker Associations and Clinical Outcomes in Metastatic Gastric Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.